The only licensed treatment for the reduction in recurrence of overt hepatic encephalopathy (OHE)1


Evidence supporting TARGAXAN® 550mg treatment in the UK & Republic of Ireland:

Go to Pivotal Trial Data

Pivotal Trial Data

Go to Long-term Data

Long-term Data

Go to Real world evidence

Real world evidence

Go to National guidelines

National guidelines

The impact of hepatic encephalopathy (HE)2

Hepatic encephalopathy is a major complication of cirrhosis.2

Approximately 50% of people with cirrhosis will develop clinically apparent hepatic encephalopathy at some stage after diagnosis - the risk being around 5-25% within 5 years.2

Hospital admissions are common and inpatient stays often prolonged. The presence of hepatic encephalopathy is associated with a significant increase in mortality; survival after the first episode is 42% at 1 year and 23% at 3 years.2

What are the potential benefits of TARGAXAN® therapy?

Compared to placebo plus lactulose, TARGAXAN® plus lactulose has been proven to:


Reduce further OHE breakthrough episodes by 23.8%
(absolute reduction; 58% relative reduction) 3
Protecting your patients from the severe cumulative negative effects of each OHE episode 4
Reduce OHE-related hospitalisations by 9%
(absolute reduction; 50% relative reduction) 3
Easing the burden on your healthcare system 5
Significantly improve patients’ QoL
(p values ranged from 0.0022 to 0.0436) 6
Corresponding to improvement in fatigue, abdominal symptoms, systemic symptoms, activity, emotional function and worry 6

 
Common adverse reactions are dizziness, headache, depression, dyspnoea, upper abdominal pain, abdominal distension, diarrhoea, nausea, vomiting, ascites, rashes, pruritus, muscle spasms, arthralgia and peripheral oedema. 1
For a full list of adverse reactions, please refer to the TARGAXAN® Summary of Product Characteristics.

Adverse event reporting


United Kingdom

The Yellow Card Scheme is run by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission on Human Medicine (CHM).

The scheme is used to collect information from health professionals and patients on suspected adverse drug reactions (ADRs). The continued success of the Yellow Card Scheme depends on your willingness to report suspected adverse drug reactions.

Both health professionals and patients can submit information through the Yellow Card website.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Republic of Ireland

Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2;

Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; Email: medsafety@hpra.ie.

You can also report to Norgine directly on Tel: 01895 826606 or Email: medinfo@norgine.com.
UK/XIF5/0719/0519 DOP: October 2019

Request a representative visit

If you wish to contact us, please provide your email address and someone will be in contact with you soon.
In submitting your email, you are giving permission for Norgine to contact you about your query. Your details will not be used for any other purpose.

Under the General Data Protection Regulation 2016 (EU) 2016/679, we have a legal duty to protect any personal information we collect from you.

Please refer to our policies page for further information.

References

  1. TARGAXAN® 550 Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/medicine/27427
  2. National Institute for Health and Care Excellence (NICE). National guideline 50 - Cirrhosis in over 16s: assessment and management. July 2016. Available at: https://www.nice.org.uk/guidance/ng50/resources/cirrhosis-in-over-16s-assessment-and-management-1837506577093
  3. Bass NM, et al. N Engl J Med 2010;362(12):1071-81
  4. Bajaj J S, Schubert C M et al. Gastroenterol 2010;138:2332-2340
  5. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  6. Sanyal A, et al. Aliment Pharmacol Ther 2011;34:853-861